Senti Biosciences, Inc. (SNTI)

NASDAQ: SNTI · IEX Real-Time Price · USD

2.426

-0.014 (-0.57%)

Jul 22, 2024, 10:04 AM EDT - Market open

Senti Biosciences Employees

Senti Biosciences had 48 employees as of December 31, 2023. The number of employees decreased by 74 or -60.66% compared to the previous year.

Employees

48

Change (1Y)

-74

Growth (1Y)

-60.66%

Revenue / Employee

$26,563

Profits / Employee

-$1,342,646

Market Cap

11.10M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	48	-74	-60.66%
Dec 31, 2022	122	33	37.08%
Dec 31, 2021	89	-	-

Related Stocks

Company Name	Employees
Mustang Bio	80
RedHill Biopharma	53
Calidi Biotherapeutics	41
Vaccinex	40
Dominari Holdings	28
Traws Pharma	18
BioRestorative Therapies	11
Cardio Diagnostics Holdings	9

Employee Rankings

SNTI News

6 days ago - Senti Bio Announces Reverse Stock Split - GlobeNewsWire
21 days ago - Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - GlobeNewsWire
2 months ago - Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire
2 months ago - Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - GlobeNewsWire
2 months ago - Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) - GlobeNewsWire
4 months ago - Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights - GlobeNewsWire
7 months ago - Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - GlobeNewsWire
7 months ago - Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire